Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly that activates three key metabolic pathways simultaneously. Unlike current GLP-1 agonists like semaglutide or dual GIP/GLP-1 therapies like tirzepatide, retatrutide adds glucagon receptor activation for enhanced metabolic benefits.
Triple Receptor Mechanism
Retatrutide is the first molecule to simultaneously engage all three receptors implicated in energy balance and body weight regulation:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, improves glycemic control — the same pathway as semaglutide (Ozempic/Wegovy)
- GIP receptor: Enhances insulin secretion and may contribute to fat mobilization — the same dual pathway as tirzepatide (Mounjaro/Zepbound)
- Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, and drives thermogenesis — a pathway unique to retatrutide among obesity therapeutics
Clinical Significance
In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide achieved a mean body weight reduction of 24.2% at 48 weeks — with some participants losing over 30% of their body weight. This represents a significant advance over existing single-agonist (semaglutide: ~15-17%) and dual-agonist (tirzepatide: ~20-22%) approaches.
Phase 3 trials are currently underway to confirm these results in larger populations and evaluate long-term safety. Retatrutide is not yet approved by the FDA or any regulatory body. All data presented on this site reflects published clinical research and should not be interpreted as medical advice.
Why Researchers Are Studying It
Retatrutide is the first investigational molecule to engage all three major hormonal pathways governing energy balance in a single compound. The glucagon receptor component is of particular research interest — in published studies it is associated with increased basal metabolic rate and hepatic fat oxidation, mechanisms not targeted by currently approved single- or dual-agonist medications. Whether this translates into an approved therapy depends on the outcome of the ongoing Phase 3 program. Retatrutide remains investigational and is not FDA-approved.